glucagon-like

Glucagon-like peptide 1 (1-37), human (TFA), is a highly potent agonist of the GLP-1 receptor and is a pancreatic hormone synthesized through post-translational processing of proglucagon.

Glucagon-like peptide 1 (1-37), human, is a highly potent agonist of the GLP-1 receptor and a pancreatic hormone synthesized through post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats.

Glucagon-like peptide 1 (1-37), human acetate 是一种高效的 GLP-1 受体激动剂。

Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a po

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human 是一种被 C 端标记的生物素化 GLP-1(7-36) 酰胺。

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide 是一种带有生物素标签的Glucagon-like peptide-1-(7-36)，后者为一种具备提升胰岛素释放功能，从而表现出抗糖尿病活性的胃肠道肽。

Exendin-4 (Exenatide) 是一种长效的 glucagon-likepeptide-1 受体激动剂(IC50: 3.22 nM)，是一种由 39 个氨基酸组成的多肽。

GLP-1(7-36), amide (MKC 253) 是一种生理性肠降血糖素，能够刺激胰岛素分泌。

Survodutide (BI 456906) 是一种胰高血糖素和胰高血糖素样肽 1 (GLP-1) 受体 (GLP Receptor) 双重激动剂,可降低 HbA1c16 型糖尿病的体重。

GLP-1(1-36) amide (human, rat)（人类及大鼠的胰高血糖素样肽1（1-36）酰胺）是GLP-1(7-36)酰胺的一种分子变体。该化合物能激发[14C]氨基吡啶在大鼠胃壁细胞的酶分散体中积累。

GLP-1(7-36), amide acetate（胰高血糖素样肽-1（7-36）酰胺醋酸盐）是GLP-1的衍生物。GLP-1(7-36), amide能够激活GLP-1受体，具有促进胰岛素分泌和抑制胰高血糖素分泌的作用，具有治疗2型糖尿病和肥胖的潜力。

GLP-2(1-33) (human) is an enteroendocrine hormone that stimulates intestinal epithelium growth.

Avexitide acetate (exendin 9-39）是一种有效的胰高血糖素样肽 1 受体 (GLP-1R) 拮抗剂，可用于研究肥胖后低血糖。

Semaglutide 是人胰高血糖素样肽-1受体激动剂，是一种人胰高血糖素样肽-1 的长效类似物。它有用于 2 型糖尿病研究的潜力。

Semaglutide Acetate 是 GLP-1R 激动剂 (EC50=6.2 pM) ，具有长效性、选择性、竞争型、口服有效性。Semaglutide acetate 可用于 2 型糖尿病的研究。

Liraglutide (Liraglutida) 是一种人工合成的胰高血糖素样肽-1 (GLP-1) 的类似物，是 GLP-1 受体的激动剂。Liraglutide 可以用于治疗 2 型糖尿病和慢性肥胖症。

Retatrutide (LY3437943) 是胰高血糖素受体、葡萄糖依赖性促胰岛素多肽受体和胰高血糖素样肽-1 受体三重激动剂,对GCGR、GIPR 和 GLP-1R 具有抑制作用。Retatrutide 可用研究肥胖症。

Tirzepatide (LY-3298176) 是葡萄糖依赖性多肽 (GIP) (EC50=0.042 nM) 和胰高血糖素样肽-1 (GLP-1) (EC50=0.086 nM) 受体双重激动剂。Tirzepatide 具有神经保护活性，可改善血压并降低低密度脂蛋白 (LDL) 胆固醇和甘油三酯，可以用于研究糖尿病和肥胖症。

Tirzepatide (LY3298176) Acetate(2023788-19-2 free base) 是一种新分子，能够通过结合葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体的双重激动作用来控制血糖水平。[3]

Avexitide (Exendin-3 (9-39) amide) 是一种特异竞争性的glucagon-like peptide-1 (GLP-1)受体拮抗剂。

Oxyntomodulin acetate 是一种 37 个氨基酸的肽激素，是一种胰高血糖素样肽 1 (GLP-1) 受体激动剂。

Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist(EC50 value of 0.06 nM),and for treatment of type 2 diabetes

Teduglutide (ALX-0600) 是一种胰高血糖素样肽-2 类似物，可增加肠道吸收，通过促进粘膜生长、减少粘膜生长来改善肠道康复，可用于研究短肠综合征 （SBS）。Teduglutide 可激活 (NR4a1)/nur77 表达和 FXR 信号传导，缓解小鼠的肠功能不全，改善肺损伤，可用于研究代谢疾病和心血管疾病。

GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003). GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2 References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003).